Good glycemic control remains crucial in prevention of late diabetic complications - The Linköping Diabetes Complications Study

Pediatric Diabetes

Volumn 10, Issue 3, 2009, Pages 168-176

  Nordwall, Maria ^a   Arnqvist, Hans J ^a   Bojestig, Mats ^a   Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Blood pressure; C peptide; Diabetic nephropathy; Diabetic retinopathy; Glycosylated; Hemoglobin A

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; ONSET AGE; PATHOGENESIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING; SWEDEN;

AGE OF ONSET; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-PEPTIDE; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; TRIGLYCERIDES;

EID: 65449153947     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00472.x     Document Type: Article

References (29)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993: 329: 977-986.
2. Nordwall M, Hyllienmark L, Ludvigsson J. Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment. J Pediatr Endocrinol Metab 2006: 19: 45-54.
3. Olsen BS, Johannesen J, Sjolie AK et al. Metabolic control and prevalence of microvascular complications in young Danish patients with type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood. Diabet Med 1999: 16: 79-85.
4. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994: 330: 15-18.
5. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes-the Linkoping Diabetes Complications Study. Diabetologia 2004: 47: 1266-1272.
6. Kullberg CE, Bergstrom A, Dinesen B et al. Comparisons of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 1996: 19: 726-729.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993: 329: 1456-1462.
8. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. Kidney Int 2001: 60: 219-227.
9. Ebeling P, Koivisto VA. Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland. Acta Diabetol 1997: 34: 33-38.
10. Sjolie AK, Stephenson J, Aldington S et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997: 104: 252-260.
11. Klein R, Zinman B, Gardiner R et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: The Renin-Angiotensin System Study. Diabetes 2005: 54: 527-533.
12. Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 2002: 51: 1580-1587.
13. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005: 28: 1649-1655.
14. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001: 24: 1275-1279.
15. Klein BE, Klein R, Mc Bride PE et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004: 164: 1917-1924.
16. Torffvit O, Lovestam-Adrian M, Agardh E, Agardh CD. Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: A 12-year observation study of 462 patients. Diabet Med 2005: 22: 723-729.
17. van Hecke MV, Dekker JM, Stehouwer CD et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: The EURODIAB prospective complications study. Diabetes Care 2005: 28: 1383-1389.
18. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994: 17: 126-131.
19. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 1995: 18: 785-792.
20. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998: 128: 517-523.
21. Winocour PH, Jeacock J, Kalsi P, Gordon C, Anderson DC. The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications. Diabetes Res Clin Pract 1990: 9: 23-35.
22. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989: 320: 1161-1165.
23. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997: 46: 1829-1839.
24. Earle K, Walker J, Hill C, Viberti G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992: 326: 673-677.
25. Fagerudd JA, Pettersson-Fernholm KJ, Gronhagen-Riska C, Groop PH. The impact of a family history of type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with type I (insulin-dependent) diabetes mellitus. Diabetologia 1999: 42: 519-526.
26. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: The EURODIAB IDDM Complications Study. Diabet Med 1998: 15: 418-426.
27. Barzilay J, Warram JH, Bak M, Laffel LM, Canessa M, Krolewski AS. Predisposition to hypertension: Risk factor for nephropathy and hypertension in IDDM. Kidney Int 1992: 41: 723-730.
28. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002: 62: 963-970.
29. Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: A population-based study in northern Sweden. Diabetes Care 2004: 27: 955-962.